AbbVie Inc (ABBV)
163.80
+2.98
(+1.86%)
USD |
NYSE |
May 03, 16:00
163.50
-0.30
(-0.18%)
After-Hours: 20:00
AbbVie Enterprise Value: 331.34B for May 2, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 02, 2024 | 331.34B |
| May 01, 2024 | 332.96B |
| April 30, 2024 | 334.58B |
| April 29, 2024 | 332.60B |
| April 26, 2024 | 329.24B |
| April 25, 2024 | 342.82B |
| April 24, 2024 | 343.72B |
| April 23, 2024 | 346.80B |
| April 22, 2024 | 343.88B |
| April 19, 2024 | 341.26B |
| April 18, 2024 | 338.16B |
| April 17, 2024 | 337.43B |
| April 16, 2024 | 334.41B |
| April 15, 2024 | 332.87B |
| April 12, 2024 | 333.95B |
| April 11, 2024 | 343.22B |
| April 10, 2024 | 345.90B |
| April 09, 2024 | 347.86B |
| April 08, 2024 | 347.26B |
| April 05, 2024 | 347.62B |
| April 04, 2024 | 343.90B |
| April 03, 2024 | 360.59B |
| April 02, 2024 | 366.54B |
| April 01, 2024 | 366.67B |
| March 31, 2024 | 369.04B |
| Date | Value |
|---|---|
| March 28, 2024 | 369.04B |
| March 27, 2024 | 365.94B |
| March 26, 2024 | 363.89B |
| March 25, 2024 | 362.72B |
| March 22, 2024 | 362.58B |
| March 21, 2024 | 360.90B |
| March 20, 2024 | 358.72B |
| March 19, 2024 | 364.72B |
| March 18, 2024 | 362.65B |
| March 15, 2024 | 361.57B |
| March 14, 2024 | 367.45B |
| March 13, 2024 | 365.07B |
| March 12, 2024 | 366.95B |
| March 11, 2024 | 364.67B |
| March 08, 2024 | 363.29B |
| March 07, 2024 | 366.33B |
| March 06, 2024 | 367.20B |
| March 05, 2024 | 363.84B |
| March 04, 2024 | 360.10B |
| March 01, 2024 | 362.65B |
| February 29, 2024 | 357.59B |
| February 28, 2024 | 361.04B |
| February 27, 2024 | 362.79B |
| February 26, 2024 | 362.47B |
| February 23, 2024 | 361.20B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
122.05B
Minimum
Mar 23 2020
375.07B
Maximum
Apr 08 2022
266.27B
Average
281.42B
Median
May 14 2021
Enterprise Value Benchmarks
| Amgen Inc | 202.86B |
| Johnson & Johnson | 368.22B |
| Eli Lilly and Co | 742.13B |
| Merck & Co Inc | 352.90B |
| Pfizer Inc | 215.28B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.369B |
| Revenue (Quarterly) | 12.31B |
| Total Expenses (Quarterly) | 9.348B |
| EPS Diluted (Quarterly) | 0.77 |
| Gross Profit Margin (Quarterly) | 66.74% |
| Profit Margin (Quarterly) | 11.12% |
| Earnings Yield | 2.06% |
| Operating Earnings Yield | 4.68% |
| Normalized Earnings Yield | 2.294 |